Product Images Rivaroxaban

The provided text appears to be a statistical analysis presenting hazard ratios and 95% confidence intervals for comparisons between Rivaroxaban and Warfarin in different patient groups based on factors such as prior Warfarin use, age, gender, weight, prior stroke/TIA, diabetic status, CHADS2 score, creatinine clearance, geographic region, and ASA use at randomization. The data includes percentage of events per year for each group. This analysis may be useful for assessing the effectiveness and safety of Rivaroxaban compared to Warfarin in specific patient subpopulations.*

This text provides information on the population description based on various factors such as end-stage renal disease, renal impairment (severe, moderate, mild), age groups, body weight ranges, and hepatic impairment. The data includes fold change and 90% confidence intervals for different conditions like postdialysis, normal, and impairment categories. The findings are related to rivaroxaban post hemodialysis in subjects with end-stage renal disease and varying levels of creatinine clearance.*

This section provides information on the interaction between drugs and their pharmacokinetics (PK) in fold change and 90% confidence intervals (CI). It includes data on various medications such as ketoconazole, ritonavir, clarithromycin, erythromycin, fluconazole, rifampicin, aspirin, atorvastatin, clopidogrel, digoxin, enoxaparin, metolazone, midazolam, naproxen, omeprazole, ranitidine, and others. The table also shows the impact of combined P-glycoprotein (P-gp) and strong/modeerate CYP3A inhibitors or inducers on drug exposure. Additionally, it displays the changes relative to Rivaroxaban alone.*

This is a comparison of cumulative event rates over time between two anticoagulants, Rivaroxaban and Warfarin. The data includes hazard ratio and confidence interval information, as well as the number of subjects at risk for each drug at different time points from randomization. This information can be used to assess and compare the effectiveness of the two medications.*

The text appears to be a medical document with data related to patient characteristics, treatments, and outcomes in a study comparing Rivaroxaban and Warfarin. The information includes patient demographics, CHADS2 score, medication usage, hazard ratios, and 95% confidence intervals. The study seems to evaluate the effectiveness and safety of these anticoagulant medications.*

This text appears to show a graph or chart related to a cumulative event rate over a period of time, with the x-axis representing days from randomization and the y-axis representing the event rate (%) or hazard ratio with a 95% confidence interval. The text also includes notation of the number of patients at risk at different time points.*

This text provides information about a medication containing rivaroxaban 10 mg in tablet form. It includes storage instructions, dosing information, and details on dispensing the Medication Guide to patients. The tablets should be stored at 20°C to 25°C with excursions permitted between 15°C to 30°C. The medication is manufactured by Sunshine Lake Pharma Co., Ltd. in GuangDong Province, China and is available in a pack of 30 tablets.*

This text provides information about Rivaroxaban tablets containing 15 mg. It includes storage instructions, manufacturer details (Sunshine Lake Pharma Co., Ltd.), NDC code (48792-7873-1), and a recommendation to dispense the medication guide to each patient. The dosage information is advised to be checked in the package insert. The tablets should be stored at 20° to 25°C, with excursions allowed between 15° to 30°C.*

This is information about rivaroxaban tablets containing 20 mg. It includes details on dosage, storage conditions, manufacturer information, and a cautionary note to keep out of reach of children. The medication guide should be dispensed to each patient. The tablets are manufactured by Sunshine Lake Pharma Co., Ltd. in GuangDong Province, China.*